Clinician perspectives on current issues in lung cancer drug development
Carcinoma, Non-Small-Cell Lung
Receptor, Epidermal Growth Factor
Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy.